#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz

Forum Diabetologicum - Issue 3/2019

Review Article

165
Diabetic cardiomyopathy and heart failure

Ján Murín, Jozef Bulas, Martin Wawruch

170
What is actually the cardiovascular risk related to type 2 diabetes?

Ivan Tkáč

174
Cardiorenal syndrome and gliflozins

Alena Šmahelová

178
Obesity, diabetes mellitus and cardiovascular disease: dangerous metabolic triad

Ubomíra Fábryová

185
The role of a fixed-ratio titratable combination of iGlarLixi in type 2 diabetes mellitus therapeutic regimen

Emil Martinka

193
The EMPRISE study (Real World Evidence): empagliflozin is reducing number of hospitalizations for heart failure, even in patients without cardiovascular disease

Emil Martinka

200
Cardiovascular studies and gliflozins

Jindřich Špinar, Lenka Špinarová, Jiří Vítovec

208
Dulaglutide and cardiovascular outcomes in patients with type 2 diabetes: REWIND study

Ivan Tkáč

213
Continuous monitoring of blood glucose in diabetes mellitus management – aid in individualization of treatment

Dana Prídavková, Udovít Šutarík, Peter Galajda, Marián Mokáň

Forum Diabetologicum

Issue 3
2019 Issue 3
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#